| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Brown A | |
| Slatopolsky E | |||
| Dusso A | |||
| P921 | main subject | hyperparathyroidism | Q1344835 |
| P304 | page(s) | S14-9 | |
| P577 | publication date | 1999-12-01 | |
| P1433 | published in | Kidney International. Supplement | Q26842696 |
| P1476 | title | Pathogenesis of secondary hyperparathyroidism | |
| P478 | volume | 73 |
| Q33821566 | A randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney disease |
| Q36906034 | Activator protein 2alpha mediates parathyroid TGF-alpha self-induction in secondary hyperparathyroidism |
| Q40179229 | Allosteric modulation of the calcium-sensing receptor |
| Q36046549 | Application of total parathyroidectomy with auto-transplantation for uremia secondary hyperparathyroidism treatment. |
| Q36079391 | Association between ambient carbon monoxide and secondary hyperparathyroidism in nondiabetic patients undergoing peritoneal dialysis |
| Q37034270 | CKD-MBD: impact on management of kidney disease. |
| Q35825603 | CYP2D6, GST-M1 and GST-T1 enzymes: expression in parathyroid gland and association with the parathyroid hormone concentration during early renal replacement therapy |
| Q34640062 | Calcium-deficiency assessment and biomarker identification by an integrated urinary metabonomics analysis |
| Q37125654 | Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study |
| Q37916534 | Cinacalcet: a pharmacoeconomic review of its use in secondary hyperparathyroidism in end-stage renal disease |
| Q37535964 | Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride |
| Q36138126 | Comparison of total parathyroidectomy without autotransplantation and without thymectomy versus total parathyroidectomy with autotransplantation and with thymectomy for secondary hyperparathyroidism: TOPAR PILOT-Trial |
| Q37101624 | Differential effects of intermittent PTH(1-34) and PTH(7-34) on bone microarchitecture and aortic calcification in experimental renal failure |
| Q85961108 | EARLIER: an observational study to evaluate the use of cinacalcet in incident hemodialysis patients with secondary hyperparathyroidism in daily clinical practice |
| Q33917786 | Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease |
| Q44186583 | Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients--results of the Austrian cohort of the ECHO study |
| Q57216887 | Effects of calcium carbonate, sevelamer hydrochloride or pantoprazole on the pharmacokinetics of cinacalcet |
| Q78421820 | Eight parathyroid glands incidentally discovered during a surgical intervention for secondary hyperparathyroidism: an unusual clinical finding |
| Q36207167 | Geographic variation of parathyroidectomy in patients receiving hemodialysis: a retrospective cohort analysis |
| Q36668070 | Impaired vitamin D metabolism in CKD |
| Q47275858 | Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis |
| Q34366087 | Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism? |
| Q27011288 | Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis |
| Q37449576 | Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism |
| Q43233976 | Meta-analysis: the efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease |
| Q36994038 | Mineral metabolic abnormalities and mortality in dialysis patients |
| Q36561062 | Minimizing bone abnormalities in children with renal failure |
| Q37691299 | New therapies: calcimimetics, phosphate binders and vitamin D receptor activators. |
| Q36947028 | Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease |
| Q37778787 | Parathyroid hormone and growth in chronic kidney disease |
| Q47423087 | Parathyroid hormone and its fragments in children with chronic renal failure |
| Q40299217 | Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients |
| Q42596981 | Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study |
| Q58750935 | Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan |
| Q33566596 | Phosphate and cardiovascular disease |
| Q58715560 | Prognosis and determinants of serum PTH changes over time in 1-5 CKD stage patients followed in tertiary care |
| Q35234337 | Progression of glomerular and tubular disease in pediatrics |
| Q44141652 | Relationship between serum 1,25-dihydroxyvitamin D and mortality in patients with pre-dialysis chronic kidney disease |
| Q86793468 | Relevance of bilateral cervical thymectomy in patients with renal hyperparathyroidism: analysis of 161 patients undergoing reoperative parathyroidectomy |
| Q37108009 | Risk factors associated with secondary hyperparathyroidism in patients with chronic kidney disease |
| Q55413395 | Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy. |
| Q37145404 | Safety of parathyroid hormone for the treatment of osteoporosis |
| Q36880126 | Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction. |
| Q36666922 | The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism |
| Q50101289 | The Use of Vitamin D Metabolites and Analogues in the Treatment of Chronic Kidney Disease |
| Q35826159 | The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis |
| Q33506544 | Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol |
| Q49825343 | Unplanned 30-Day Readmissions after Parathyroidectomy in Patients with Chronic Kidney Disease: A Nationwide Analysis. |
| Q35614174 | Vitamin D Binding Protein Is Not Involved in Vitamin D Deficiency in Patients with Chronic Kidney Disease |
| Q37722852 | Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality |
| Q36947025 | Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies |
| Q35123615 | Vitamin D resistance in chronic kidney disease (CKD). |
Search more.